Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States

被引：0
|
作者：
Farber, Harrison W. [1 ]
Germack, Hayley D. [2 ]
Croteau, Nicole S. [3 ]
Simeone, Jason C. [3 ]
Tang, Fei [3 ]
Paoli, Carly J. [2 ]
Doad, Gurinderpal [4 ]
Panjabi, Sumeet [2 ]
De Marco, Teresa [5 ]
机构：
[1] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02111 USA
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
[3] Cytel, Real World Evidence, Waltham, MA USA
[4] Actelion Pharmaceut, Titusville, NJ USA
[5] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA
来源：
PULMONARY CIRCULATION | 2024年 / 14卷 / 02期
关键词：
pulmonary arterial hypertension; risk factors; treatment;
D O I：
10.1002/pul2.12326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated With Congenital Heart Disease in Chinese Children: Similarities, Differences, and Prognostic Factors
    Gu, Li
    Li, Yuan Yuan
    Gu, Ling
    Xie, Liang
    Liu, Han Min
    FRONTIERS IN PEDIATRICS, 2020, 8
  • [22] Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances
    Maron, Bradley A.
    Abman, Steven H.
    Elliott, C. Greg
    Frantz, Robert P.
    Hopper, Rachel K.
    Horn, Evelyn M.
    Nicolls, Mark R.
    Shlobin, Oksana A.
    Shah, Sanjiv J.
    Kovacs, Gabor
    Olschewski, Horst
    Rosenzweig, Erika B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (12) : 1472 - 1487
  • [23] Natural plant products in treatment of pulmonary arterial hypertension
    Xiang, Lili
    Li, Ying
    Deng, Xu
    Kosanovic, Djuro
    Schermuly, Ralph Theo
    Li, Xiaohui
    PULMONARY CIRCULATION, 2018, 8 (03)
  • [24] Selexipag for the treatment of pulmonary arterial hypertension
    Genecand, Leon
    Wacker, Julie
    Beghetti, Maurice
    Lador, Frederic
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (05) : 583 - 595
  • [25] Macitentan for the Treatment of Pulmonary Arterial Hypertension
    Hong, Irene S.
    Coe, Holly V.
    Catanzaro, Linda M.
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (04) : 538 - 547
  • [26] Macitentan for the treatment of pulmonary arterial hypertension
    Sood, Namita
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (18) : 2733 - 2739
  • [27] Guidelines for the Treatment of Pulmonary Arterial Hypertension
    Zoë G. S. Vazquez
    James R. Klinger
    Lung, 2020, 198 : 581 - 596
  • [28] Selexipag for the treatment of pulmonary arterial hypertension
    Skoro-Sajer, Nika
    Lang, Irene Marthe
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (03) : 429 - 436
  • [29] Tadalafil for the treatment of pulmonary arterial hypertension
    Rosenzweig, Erika B.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (01) : 127 - 132
  • [30] Update on the Treatment of Pulmonary Arterial Hypertension
    Fernandes, Caio J.
    Calderaro, Daniela
    Luppino Assad, Ana Paula
    Salibe-Filho, William
    Kato-Morinaga, Luciana Tamie
    Hoette, Susana
    Piloto, Bruna
    Castro, Marcela Araujo
    Lisboa, Roberta Pontes
    Felix da Silva, Taysa Antonia
    Martins, Murillo de Araujo
    Alves-Jr, Jose L.
    Jardim, Carlos
    Terra-Filho, Mario
    de Souza, Rogerio
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2021, 117 (04) : 750 - 763
12345